First in Human Study of SIM0610 in Solid Tumors

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Clinical Phase

PHASE1

Total Enrollment

260 participants

Study Classification

INTERVENTIONAL

Study Start Date

2026-01-19

Study Completion Date

2029-07-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This is a multicenter, open-label, first-in-human (FIH) study to evaluate the safety, tolerability, pharmacokinetic/pharmacodynamic profile, and preliminary antitumor activity of SIM0610 in subjects with locally advanced/metastatic solid tumors. Accelerated titration (ATD) and Bayesian optimal interval design (BOIN) will be used to guide dose escalation in part1, the preliminary anti-tumor effect of SIM0610 will to be further evaluated in part 2.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

A Phase I Study of SIM0609 in Adult Participants With Locally Advanced/Metastatic Solid Tumors

NCT07265921

Advanced Solid Cancer

RECRUITING PHASE1

A Phase I Study of SIM0686 in Participants With Locally Advanced/Metastatic Solid Tumors

NCT07050459

Locally Advanced Solid Tumors

RECRUITING PHASE1

A Study to Investigate the Safety, Tolerability, Pharmacokinetics and Preliminary Antitumor Activity of SIM0237 in Adult Participants with Advanced Solid Tumors

NCT05781360

Locally Advanced Unresectable or Metastatic Solid Tumor

TERMINATED PHASE1

A Phase I Study of SIM0505 in Participants With Advanced Solid Tumors

NCT06792552

Advanced Solid Tumors

RECRUITING PHASE1

Study of ISM3412 in Participants With Locally Advanced/Metastatic Solid Tumors

NCT06414460

Locally Advanced/Metastatic Solid Tumors

RECRUITING PHASE1

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Advanced Solid Tumours Non-Small Cell Lung Cancer Colorectal Cancer Head and Neck Squamous Cell Carcinoma Hepatocellular Carcinoma

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Intervention Model

SEQUENTIAL

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Dose escalation

SIM0610 administered intravenously at selected dose levels according to protocol

Group Type EXPERIMENTAL

SIM0610 for Injection

Intervention Type DRUG

intravenous infusion

Cohort expansion

SIM0610 administered intravenously at Recommended dosage(RDs) according to protocol

Group Type EXPERIMENTAL

SIM0610 for Injection

Intervention Type DRUG

intravenous infusion

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

SIM0610 for Injection

intravenous infusion

Intervention Type DRUG

SIM0610 for Injection

intravenous infusion

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Voluntarily participate and sign the informed consent form
* At least 18 years old, male or female
* Subjects with locally advanced/metastatic solid tumors confirmed by histology and/or cytology;
* Subjects in Part 1 should have at least one tumor lesion evaluable by RECIST v1.1 criteria, and subjects in Part 2 should have at least one measurable tumor lesion by RECIST v1.1 (lesions that have received radiotherapy or other local treatments cannot be used as target lesions unless there is clear progression of the lesion)
* Subjects with locally advanced/metastatic solid tumors who have failed standard treatment: Part 1: Subjects with solid tumors who have experienced disease progression during/after at least one previous standard systemic anti-tumor regimen and are not suitable for standard treatment. Part 2: Non-small cell lung cancer, liver cancer, head and neck squamous cell carcinoma, colorectal cancer that have experienced disease progression during/after at least one previous standard systemic anti-tumor regimen and are not suitable for standard treatment
* Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
* Expected survival period ≥ 12 weeks
* Adequate organ and bone marrow function
* Archived formalin-fixed, paraffin-embedded (FFPE) tumor tissue or fresh biopsy tissue within 5 years must be provided before the first administration

Exclusion Criteria

* A history of active second primary malignancy within the past 2 years, except for localized tumors that are considered cured and have a low risk of recurrence as assessed by the investigator.
* Symptomatic central nervous system (CNS) metastases occurring within 2 weeks prior to the first dose of study treatment; or requirement for local therapy (e.g., radiotherapy or surgery) for CNS metastases; or requirement for corticosteroid therapy for CNS metastases.
* A history of non-infectious interstitial lung disease (ILD)/pulmonary inflammation requiring corticosteroid treatment; current ILD/pulmonary inflammation; or suspected ILD/pulmonary inflammation that cannot be ruled out by screening imaging.
* Uncontrolled pleural effusion, pericardial effusion, or ascites, or occurrence of such effusions requiring drainage or medical intervention within 4 weeks prior to the first dose of study treatment.
* Failure to recover from adverse events (AEs) induced by prior anti-tumor therapy (i.e., recovery to Grade 1 or baseline level).
* Current participation in a study involving investigational drugs or medical devices, or participation in such a study within 4 weeks prior to the first dose of study treatment.
* Receipt of the following therapies prior to the first dose of study treatment:

1. Cytotoxic therapy within 3 weeks; or anti-tumor targeted small-molecule drugs (e.g., tyrosine kinase inhibitors) within 2 weeks.
2. Anti-tumor antibody-based immune checkpoint inhibitors, antibody-drug conjugates (ADCs), or other anti-tumor biologics within the shorter of 5 half-lives or 4 weeks.
3. Traditional Chinese medicines (TCMs)/herbal preparations with anti-tumor indications within 2 weeks.
4. Radiotherapy within 4 weeks.
* Received antibody-drug conjugate (ADC) with topoisomerase I inhibitor (TOP1i) or other ADC targeting EGFR/cMET.
* Received any live vaccine within 4 weeks prior to the first dose of study treatment.
* Received the following medications ≤ 14 days prior to the first dose of study treatment:

1. Strong or moderate CYP3A4 induction/inhibitor;
2. Drugs known to be at risk for torsade de pointes (TdP);
3. Drugs associated with QTcF interval prolongation (TdP risk equivocal).
* Known human immunodeficiency virus (HIV) infection or known acquired immunodeficiency syndrome (AIDS).
* A history of clinically significant cardiovascular diseases within 6 months prior to the first dose of study treatment, including but not limited to myocardial infarction, severe/unstable angina pectoris, primary cardiomyopathy, cerebrovascular accident (including transient ischemic attack, cerebral hemorrhage, cerebral infarction) or congestive heart failure (New York Heart Association \[NYHA\] Functional Classification \> Class II); symptomatic coronary artery disease requiring pharmacotherapy.
* A history of allogeneic organ transplantation or graft-versus-host disease (GVHD).
* A history of hypersensitivity to the active ingredients, inactive excipients of SIM0610, or drugs with similar chemical structures or classifications to SIM0610.
* Pregnant or lactating women. For women of childbearing potential (WOCBP), they are also excluded unless:

1. The result of serum pregnancy test within 72 hours prior to the first dose of study treatment is negative;
2. They use highly effective contraceptive methods from the time of signing the informed consent form (ICF) until 180 days after the last dose of study treatment.
* Male subjects with female partners of childbearing potential are excluded unless they use highly effective contraceptive methods from the time of signing the ICF until 180 days after the last dose of study treatment.
* Any other conditions that may increase subject-related risks or interfere with the interpretation of study results, and that, in the investigator's judgment, render the subject unsuitable for study enrollment.

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.